SNORD83A: A Potential Drug Target and Biomarker (G116937)

Target Name: SNORD83A

NCBI ID: G116937

SNORD83A

Other Name(s): RNU83A | Small nucleolar RNA, C/D box 83A | U83A | small nucleolar RNA, C/D box 83A

SNORD83A: A Potential Drug Target and Biomarker

SNORD83A, short for small nucleotide RNA, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and chronic obstructive pulmonary disease (COPD). SNORD83A is a key regulator of gene expression and has been shown to play a critical role in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation.

The discovery of SNORD83A as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases insights. By targeting SNORD83A, researchers can gain into the underlying mechanisms of disease and develop new treatments that target specific aspects of the disease process . Additionally, the identification of SNORD83A as a potential biomarker can be used to monitor disease progression and assess the effectiveness of treatments.

SNORD83A is a small molecule RNA that is expressed in various tissues and cells, including the brain, heart, and lungs. It is primarily translated from the mRNA molecule U17, which is derived from the genomic sequence ATCG000100023. SNORD83A has a length of approximately 200 nucleotides and consists of a single exon. The exon is transcribed from the DNA sequence ATCG000100024.

SNORD83A has been shown to play a critical role in the regulation of cellular processes, including cell growth, apoptosis, and inflammation. It is a negative regulator of the transcription factor SLAM, which is involved in the regulation of cell growth and differentiation. Additionally, SNORD83A is a negative regulator of the transcription factor p53, which is involved in the regulation of apoptosis and DNA damage repair.

SNORD83A has also been shown to play a critical role in the regulation of inflammation. It is a negative regulator of the transcription factor NF-kappa-B, which is involved in the regulation of inflammation and immune responses. Additionally, SNORD83A is a negative regulator of the Transcription factor TGF-β, which is involved in the regulation of cell proliferation and angiogenesis.

The identification of SNORD83A as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases insights. By targeting SNORD83A, researchers can gain into the underlying mechanisms of disease and develop new treatments that target specific aspects of the disease process . Additionally, the identification of SNORD83A as a potential biomarker can be used to monitor disease progression and assess the effectiveness of treatments.

In conclusion, SNORD83A is a potential drug target and biomarker that has significant implications for the development of new treatments for various diseases. The regulation of cellular processes by SNORD83A is a complex and important aspect of disease development, and the identification of SNORD83A as a potential drug target and biomarker is a promising area of 鈥嬧?媟esearch that has the potential to lead to new treatments for a variety of diseases. Further research is needed to fully understand the role of SNORD83A in disease and to develop new treatments based on its unique properties.

Protein Name: Small Nucleolar RNA, C/D Box 83A

The "SNORD83A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD83A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets